SAN DIEGO, Aug. 26, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that Christopher J. Reinhard, Chairman and Chief Executive Officer, is scheduled to present at the Southern California Investor Conference on Monday, August 29, 2011, at 9:30 a.m. (Pacific) at the Island Hotel in Newport Beach, California. The slide presentation will be available at the Company’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.
(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium’s current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium healthy lifestyle product platform. The Company’s lead product candidates include Excellagen topical gel for wound care management, and Generx® DNA-based angiogenic biologic for patients with coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.
Copyright 2011 Cardium Therapeutics, Inc. All rights reserved. | |
For Terms of Use Privacy Policy, please visit www.cardiumthx.com. | |
Cardium Therapeutics®, Generx®, Cardionovo, Tissue Repair, Gene Activated Matrix, GAM, Excellagen, Excellarate, Osteorate, MedPodium, Appexium, Linee, Alena, Cerex and Nutra-Apps are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company | |
SOURCE Cardium Therapeutics
